Microcap Ledger Revelation Biosciences, Inc. $REVB
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- Pharmaceutical Preparations
- Headquarters
- San Diego, CA
- Fiscal year end
- December 31
- Shares outstanding
- 3,983,416 [10-Q 2026-08-06]
What the company doesAI summary of filing
Revelation Biosciences is a clinical-stage biopharmaceutical company developing Gemini, a proprietary formulation based on PHAD, a toll-like receptor 4 agonist designed to modulate inflammatory responses. The company is evaluating Gemini in two kidney disease programs: GEM-AKI for acute kidney injury treatment and GEM-CKD for chronic kidney disease treatment. The company has completed preclinical studies and Phase 1 clinical studies in healthy volunteers and patients with chronic kidney disease, and plans to initiate a Phase 2/3 adaptive design study for acute kidney injury in 2026. Revelation is pre-revenue and generates no product sales. [10-K 2026-02-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | — | −$6.33M | −$5.77M | $11.48M | [10-Q 2026-08-06] |
| FY ended Dec 2025 | — | −$8.91M | −$8.27M | $10.70M | [10-K 2026-02-26] |
| FY ended Dec 2024 | — | −$15.04M | −$18.32M | $6.50M | [10-K 2026-02-26] |
- Quarterly cash burn
- −$2.89M
- Cash runway Estimate
- ~11.9 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-04 | 4,292,455 | [10-Q 2024-11-08] |
| 2025-03-03 | 905,228 | [10-K 2025-03-06] |
| 2025-05-05 | 963,796 | [10-Q 2025-05-08] |
| 2025-08-04 | 1,699,637 | [10-Q 2025-08-08] |
| 2025-11-04 | 5,924,137 | [10-Q 2025-11-06] |
| 2026-02-23 | 3,720,420 | [10-K 2026-02-26] |
| 2026-05-04 | 3,908,420 | [10-Q 2026-05-07] |
| 2026-08-03 | 3,983,416 | [10-Q 2026-08-06] |
- Shelf registration
- S-3 filed 2026-01-30; declared effective 2026-02-11 [S-3 2026-01-30]
Listing status
Current status: 2 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-01-07. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.
| Date | Event | Details | Deadline | Filing |
|---|---|---|---|---|
| 2025-01-07 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2025-01-07] |
| 2024-10-21 | 8-K Item 3.01 | Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing | — | [8-K 2024-10-21] |
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-08-17 | Rolke James | grant | 208,076 | — | [4 2026-08-18] |
| 2026-08-17 | Chawla Lakhmir S | grant | 32,011 | — | [4 2026-08-18] |
| 2026-08-17 | Zygmont Chester Stanley Iii | grant | 208,073 | — | [4 2026-08-18] |
| 2026-08-17 | Zygmont Chester Stanley Iii | other | 208,073 | — | [4 2026-08-18] |
| 2026-08-17 | Zygmont Chester Stanley Iii | other | 208,073 | — | [4 2026-08-18] |
| 2026-08-17 | Roper Jess | grant | 32,011 | — | [4 2026-08-18] |
| 2026-08-17 | Carver Jennifer | grant | 32,011 | — | [4 2026-08-18] |
| 2026-04-30 | Rolke James | other | 10,115 | $1.13 | [4 2026-05-01] |
| 2026-04-30 | Zygmont Chester Stanley Iii | other | 13,285 | $1.10 | [4 2026-05-01] |
| 2026-02-03 | Roper Jess | other | 1,591 | $1.85 | [4 2026-02-05] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-08-19 | 8-K | Director or officer change |
| 2026-08-14 | 13G/A | Beneficial ownership report (5%+ holder) |
| 2026-08-06 | 8-K | Results of operations |
| 2026-08-06 | 10-Q | Quarterly report |
| 2026-07-13 | 8-K | Material agreement entered; Change to security holder rights; Charter, bylaws or fiscal year change |
| 2026-06-24 | 8-K | Director or officer change; Charter, bylaws or fiscal year change; Shareholder vote results |
| 2026-06-01 | 8-K | Other events |
| 2026-05-15 | 13G | Beneficial ownership report (5%+ holder) |
| 2026-05-11 | DEF 14A | Proxy statement |
| 2026-05-07 | 8-K | Results of operations |
| 2026-05-07 | 10-Q | Quarterly report |
| 2026-04-30 | PRE 14A | Proxy statement |
Alerts for $REVB
Email me when Revelation Biosciences, Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.